Ultrasound Stiffness Imaging in Crohn's Disease
Status: | Completed |
---|---|
Conditions: | Gastrointestinal, Crohns Disease |
Therapuetic Areas: | Gastroenterology |
Healthy: | No |
Age Range: | 18 - 75 |
Updated: | 4/21/2016 |
Start Date: | September 2012 |
End Date: | July 2015 |
Investigating Ultrasound Stiffness Imaging for Predicting Outcomes in Crohn's Disease
The purpose of this study is to determine whether ultrasound-based assessment of intestinal
stiffness in patients with Crohn's disease predicts the effectiveness of medical therapy or
the need for surgical resection.
stiffness in patients with Crohn's disease predicts the effectiveness of medical therapy or
the need for surgical resection.
Modern medical therapy in Crohn's disease, including immunomodulators and biologic
compounds, has revolutionized disease treatment. However, a significant portion of
individuals will not respond to medications, most often due to the development of intestinal
fibrosis. Over the course of Crohn's disease repeated episodes of inflammation and abnormal
wound healing lead to progressive intestinal fibrosis, strictures, and bowel obstruction.
While inflammatory Crohn's disease often responds to medical therapy, predominantly
fibrostenotic intestinal disease is unresponsive and requires surgery. Our inability to
accurately distinguish intestinal inflammation from fibrosis frequently leads to empiric
trials of steroids and immunosuppressive therapies. This often proves futile, delays
inevitable surgery, and unnecessarily exposes the patient to medication-related risks for
months and sometimes years. At present there are no available means to distinguish medically
responsive inflammatory disease from predominately fibrotic intestinal disease. The unmet
need in this field is an accurate diagnostic technology to determine which patients will
benefit from anti-inflammatory therapy, and which patients should go directly to surgery.
Non-invasive ultrasound stiffness imaging (USI) may be a surrogate marker of underlying
bowel wall fibrosis that aids in predicting if Crohn's disease will be responsive to medical
therapy.
Two USI methods have recently been developed: Ultrasound elasticity imaging (UEI) uses 2D
speckle-tracking to measure tissue strain, a surrogate of fibrosis. The second, shear wave
imaging (SWI), is a commercially available technology that measures the speed of ultrasonic
shear waves through tissue. Shear waves travel more rapidly through stiff tissue. The
central hypothesis of this proposal is that ultrasound stiffness imaging (USI)
quantitatively distinguishes predominately inflammatory from fibrotic bowel wall thickening,
and therefore is predictive of the likelihood of response to medical therapy or the need for
surgery.
We plan to objectively test our central hypothesis and attain the objective of this
application by pursuing the following three specific aims:
Specific Aim 1 (SA-1): Determine if USI stiffness measurements of intestinal strictures in
Crohn's patients admitted with small bowel obstruction predicts response or failure of
medical therapy based on CDAI and objective inflammatory biomarkers during index
hospitalization and at 90 day follow-up.
Inpatient Inclusion Criteria:
- Subjects must be 18 years of age or older
- Previous diagnosis of Crohn's disease with imaging demonstrating involvement of the
ileum
- Hospital admission imaging demonstrating small bowel dilation (to > 3.5 cm)
- CDAI score of >220.
Inpatient Exclusion Criteria:
- Active Clostridium difficile colitis/enteritis
- Presence of abdominal enterocutaneous fistulas in the ultrasound path.
- Prior abdominal hernia repair with mesh placement in the ultrasound path.
Specific Aim 2 (SA-2): Determine if USI stiffness measurements of diseased ileum in Crohn's
outpatients starting Anti-Tumor Necrosis Factor-Alpha therapy predicts response to medical
therapy based on CDAI and objective inflammatory biomarkers.
Outpatient Inclusion Criteria
- Crohn's patients age 18 and over starting anti-TNF therapy
- CDAI score > 220 to denote clinical disease activity.
Outpatient Exclusion Criteria:
- Active Clostridium difficile colitis/enteritis
- Presence of abdominal enterocutaneous fistulas in the ultrasound path
- Prior abdominal hernia repair with mesh placement in the ultrasound path
- Current use of prednisone or budesonide
- Changing anti-TNF due to allergy (including a TNF-induced lupus-like arthritis).
compounds, has revolutionized disease treatment. However, a significant portion of
individuals will not respond to medications, most often due to the development of intestinal
fibrosis. Over the course of Crohn's disease repeated episodes of inflammation and abnormal
wound healing lead to progressive intestinal fibrosis, strictures, and bowel obstruction.
While inflammatory Crohn's disease often responds to medical therapy, predominantly
fibrostenotic intestinal disease is unresponsive and requires surgery. Our inability to
accurately distinguish intestinal inflammation from fibrosis frequently leads to empiric
trials of steroids and immunosuppressive therapies. This often proves futile, delays
inevitable surgery, and unnecessarily exposes the patient to medication-related risks for
months and sometimes years. At present there are no available means to distinguish medically
responsive inflammatory disease from predominately fibrotic intestinal disease. The unmet
need in this field is an accurate diagnostic technology to determine which patients will
benefit from anti-inflammatory therapy, and which patients should go directly to surgery.
Non-invasive ultrasound stiffness imaging (USI) may be a surrogate marker of underlying
bowel wall fibrosis that aids in predicting if Crohn's disease will be responsive to medical
therapy.
Two USI methods have recently been developed: Ultrasound elasticity imaging (UEI) uses 2D
speckle-tracking to measure tissue strain, a surrogate of fibrosis. The second, shear wave
imaging (SWI), is a commercially available technology that measures the speed of ultrasonic
shear waves through tissue. Shear waves travel more rapidly through stiff tissue. The
central hypothesis of this proposal is that ultrasound stiffness imaging (USI)
quantitatively distinguishes predominately inflammatory from fibrotic bowel wall thickening,
and therefore is predictive of the likelihood of response to medical therapy or the need for
surgery.
We plan to objectively test our central hypothesis and attain the objective of this
application by pursuing the following three specific aims:
Specific Aim 1 (SA-1): Determine if USI stiffness measurements of intestinal strictures in
Crohn's patients admitted with small bowel obstruction predicts response or failure of
medical therapy based on CDAI and objective inflammatory biomarkers during index
hospitalization and at 90 day follow-up.
Inpatient Inclusion Criteria:
- Subjects must be 18 years of age or older
- Previous diagnosis of Crohn's disease with imaging demonstrating involvement of the
ileum
- Hospital admission imaging demonstrating small bowel dilation (to > 3.5 cm)
- CDAI score of >220.
Inpatient Exclusion Criteria:
- Active Clostridium difficile colitis/enteritis
- Presence of abdominal enterocutaneous fistulas in the ultrasound path.
- Prior abdominal hernia repair with mesh placement in the ultrasound path.
Specific Aim 2 (SA-2): Determine if USI stiffness measurements of diseased ileum in Crohn's
outpatients starting Anti-Tumor Necrosis Factor-Alpha therapy predicts response to medical
therapy based on CDAI and objective inflammatory biomarkers.
Outpatient Inclusion Criteria
- Crohn's patients age 18 and over starting anti-TNF therapy
- CDAI score > 220 to denote clinical disease activity.
Outpatient Exclusion Criteria:
- Active Clostridium difficile colitis/enteritis
- Presence of abdominal enterocutaneous fistulas in the ultrasound path
- Prior abdominal hernia repair with mesh placement in the ultrasound path
- Current use of prednisone or budesonide
- Changing anti-TNF due to allergy (including a TNF-induced lupus-like arthritis).
Inclusion Criteria:
- CDAI score >220
- if INPATIENT: admission for small bowel obstruction.
- if OUTPATIENT: start of anti-tumor necrosis alpha therapy
Exclusion Criteria:
- Active Clostridium difficile colitis/enteritis
- Presence of abdominal enterocutaneous fistulas in the ultrasound path
- Prior abdominal hernia repair with mesh placement in the ultrasound path
We found this trial at
1
site
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 936-4000
University of Michigan Health System The University of Michigan is home to one of the...
Click here to add this to my saved trials